Operation Whole Health · A Veterans Safety Initiative

Brain Terrain & Psychedelic Readiness

An Evidence Review — the case for safety screening and health optimization before ibogaine, psychedelic, and emerging therapies in veterans

Document: White Paper · DRAFT v0.1 — for advisory review

Prepared by: Operation Whole Health

Status: Pre-review · not for distribution

Read this first

What this document claims — and what it does not

The veteran-psychedelic field is moving fast and largely unregulated. This paper argues for one thing: that rigorous medical screening and honest health optimization before treatment is a legitimate, evidence-supported safety practice — across the whole field, from ibogaine to MDMA, ketamine, psilocybin, and beyond. It is deliberately conservative about what is proven.

Established consistent human evidence Plausible / mechanistic biologically reasonable, indirect or preclinical Hypothesis — untested not yet demonstrated in this context

Our honest position, up front:

We DO claim: pre-treatment cardiac and metabolic screening (especially for ibogaine) is Established as safety-relevant, and reducing inflammatory, vascular, and toxicant burden is a reasonable health goal for this population.
We do NOT claim that detoxification "makes psychedelics work better," that toxicants get "locked into" the brain during treatment, or that any product is required. Those are open questions we intend to help study, not marketing claims.
Conflict of interest, disclosed: Operation Whole Health develops nutritional/detox protocols and products. This paper is educational; it is not medical advice, and any protocol must be directed by the veteran's treating clinicians. The research arm and the commercial arm are intended to be kept separate.

Executive summary

The case in one page

Ibogaine and other psychedelics are being fast-tracked for veterans with traumatic brain injury (TBI), PTSD, depression, and addiction. In a Stanford observational study of 30 Special Operations veterans, a magnesium–ibogaine protocol produced large improvements in disability, PTSD, depression, and anxiety, with no serious adverse events¹. That result is striking — and notably, the protocol already pre-loads magnesium specifically to reduce ibogaine's known cardiac risk¹. In other words, the leading clinical model already accepts the core idea of this paper: prepare the patient before you treat.

This population also carries measurable, treatment-relevant burdens: neurotoxic heavy metals and environmental chemicals that cross the blood–brain barrier^9,10; chronic neuroinflammation that impairs the very neuroplasticity these therapies depend on^8,12; and altered cerebral blood flow after blast exposure and TBI^6,7. Ibogaine specifically blocks the cardiac hERG channel, prolongs the QT interval, and is metabolized by CYP2D6 — creating real, sometimes fatal, and highly individual cardiac risk^2,3,4,5.

The conclusion is modest and defensible: a standardized readiness phase — cardiac/QTc and CYP2D6 screening, medication reconciliation, and conservative optimization of the metabolic, inflammatory, and toxicant terrain — is a rational safety layer. Whether terrain optimization also improves treatment outcomes is an honest hypothesis that a registry and pilot can test.

Pillar 1 · the strongest case

Treatment-specific safety & readiness screening

This is where the evidence is firmest and where a "readiness standard" is most clearly justified. Every one of these medicines carries a signature risk that pre-treatment screening is built to catch — and the profiles differ sharply. Ibogaine's cardiac danger is the most acute and best-documented, so we use it as the worked example below; the full per-medicine detail lives in the Modality Education Library and the Protocol v1 annexes.

Medicine	Signature risk the screening targets
Ibogaine	Cardiac — QT prolongation, fatal arrhythmia; CYP2D6 metabolism
MDMA	Serotonin syndrome (with SSRIs/MAOIs); hyperthermia; hyponatremia
Ketamine	Bladder toxicity; dependence; dissociation; blood pressure
Psilocybin / LSD	Psychological (psychosis/bipolar); transient BP/HR; HPPD
Cannabis	Dose-dependent psychosis; cardiovascular; dependence
Kratom	Dependence/withdrawal; liver injury; toxicity

The universal principle is identical across all of them: screen for the medicine's specific danger, reconcile every medication, and clear the patient with the treating clinician before dosing. Ibogaine, below, shows why that discipline matters most.

Established Ibogaine carries a real, sometimes fatal, cardiac risk via hERG/QT prolongation.

Ibogaine and its long-lived metabolite noribogaine block the cardiac hERG potassium channel, delaying repolarization and prolonging the QT interval — the mechanism of potentially fatal Torsades de Pointes². A clinical review documented 27 reported fatalities, with cases of ventricular arrhythmia and QT prolongation occurring at therapeutic doses even in individuals without pre-existing cardiac disease^3,4. Because noribogaine persists for days, QT risk can extend well beyond the dosing window².

Established CYP2D6 metabolism makes ibogaine exposure highly individual — and drug interactions matter.

Ibogaine is converted to noribogaine primarily by CYP2D6³. In a controlled human study, reduced CYP2D6 activity roughly doubled active-drug exposure, leading the authors to recommend genotyping patients and at least halving the dose in poor metabolizers⁵. Critically, common medications inhibit CYP2D6 — including the SSRI paroxetine, which doubled exposure in that same study⁵. Many veterans take SSRIs and other CYP2D6-relevant drugs, making medication reconciliation a genuine safety step, not a formality.

Readiness implication (well-founded): baseline ECG/QTc, electrolytes (K⁺, Mg²⁺, Ca²⁺), cardiac history, CYP2D6 awareness, and a full medication/supplement reconciliation are defensible, clinician-welcomed pre-treatment steps. The Stanford protocol's use of magnesium to buffer cardiac risk¹ is a live example of "prepare, then treat."

Pillar 2

Toxicant body burden & the brain

Established Neurotoxic heavy metals and environmental chemicals cross the blood–brain barrier and harm brain tissue.

Lead, arsenic, manganese, cadmium and related metals cross the blood–brain barrier and, at sufficient exposure, induce oxidative stress, tight-junction loss, and neuronal dysfunction — increasing barrier permeability and driving accumulation⁹. Broader environmental toxicants (particulate matter, pesticides, solvents, heavy metals) are recognized drivers of neuroinflammation, cerebrovascular damage, and cognitive decline¹⁰. This is directly relevant to a population with documented service-related exposures.

Hypothesis — untested That reducing toxicant burden before psychedelic therapy improves its results, or prevents toxicants being "locked in" during neuroplastic change.

We are explicit: there is no direct evidence that pre-treatment detox changes psychedelic outcomes, and no established mechanism by which synaptic remodeling "traps" metals. This is a reasonable question to study — not a claim to sell. It belongs in the registry and pilot, framed as a hypothesis.

Critical safety caveat (this protects veterans and our credibility): chelation is not automatically beneficial. In controlled animal work, blood-metal levels were a poor predictor of brain-metal reduction, and chelating subjects who were not metal-overloaded produced lasting adverse neurobehavioral effects¹¹. The honest standard is therefore test-first, treat conservatively, and never chelate the un-exposed — and never near a cardiotoxic drug without physician oversight (chelation can shift the very electrolytes that govern QT risk).

Pillar 3

Neuroinflammation & neuroplasticity

Plausible / mechanistic These therapies work partly by driving neuroplasticity — and chronic neuroinflammation opposes it.

Psychedelics and related "psychoplastogens" (psilocybin, ketamine, DMT, and ibogaine's neurotrophic signaling) promote dendritic growth and synaptogenesis through BDNF–TrkB–mTOR pathways, and appear to exert anti-inflammatory/immunomodulatory effects¹². Conversely, chronic neuroinflammation — activated microglia, pro-inflammatory cytokines, reduced BDNF — is a recognized contributor to impaired plasticity and mood/cognitive dysfunction⁸. Ibogaine itself upregulates BDNF³.

Reasonable inference: if a therapy heals by inducing plasticity, the inflammatory/metabolic terrain in which that plasticity occurs plausibly matters. Optimizing sleep, inflammation, and metabolic health before treatment is a low-risk, generally beneficial goal — while stopping short of claiming it changes psychedelic efficacy (that remains Hypothesis).

Pillar 4

Cerebral perfusion in the veteran brain

Established Blast exposure and TBI alter cerebral blood flow — and perfusion tracks brain-tissue health.

In 180 military personnel, cumulative blast exposure was associated with altered cerebral perfusion even without a diagnosed moderate/severe TBI⁶. In veterans with a history of TBI, reduced cerebral blood flow was associated with poorer white-matter integrity in the chronic phase⁷. Cerebral blood flow is fundamental to maintaining neuronal integrity.

Readiness implication: cerebrovascular health is a legitimate part of "brain readiness," and a rational optimization target (blood pressure, metabolic health, vascular risk factors) — measurable and clinician-credible, without overclaiming a psychedelic-specific benefit.

The synthesis

A readiness standard — what it should (and shouldn't) be

Component	Evidence status	What it means in practice
Cardiac / QTc + electrolyte screening	Established	Baseline ECG, K⁺/Mg²⁺/Ca²⁺, cardiac history; the firmest pillar.
CYP2D6 awareness + medication reconciliation	Established	Screen interacting drugs (SSRIs, etc.); flag poor-metabolizer risk.
Toxicant assessment (test-first)	Plausible	Measure before considering any detox; never chelate the un-exposed.
Inflammation / metabolic / sleep optimization	Plausible	Low-risk general health gains; not sold as efficacy.
Cerebrovascular optimization	Established (relevance)	Vascular risk-factor management; measurable.
"Detox improves psychedelic outcomes"	Hypothesis	Study it via registry/pilot; do not market it.

The research agenda (how the hypothesis becomes evidence): a consented outcomes registry — baseline biomarkers (blood metals, hs-CRP, QTc, HRV) → protocol adherence → clinic outcome → follow-up — is the honest path to proving or disproving whether readiness/terrain optimization changes results. That dataset, not any single product, is the credible foundation for a "standard."

Operation Whole Health — a Patriot-founded 501(c)(3) initiative for veteran health. DRAFT v0.1 — for advisory review only; not for public distribution.

Disclosures & limits: This document is educational and does not constitute medical advice, a treatment protocol, or an endorsement of ibogaine or any Schedule I substance. Ibogaine is not FDA-approved and carries serious risks; any care must be directed by qualified treating clinicians. Operation Whole Health develops nutritional/detox protocols and products (conflict of interest disclosed); the intent is to separate the research/standards function from the commercial function and to seek independent clinical and toxicology advisory review before any protocol is published. Human evidence herein was retrieved from PubMed; see references.

If you or a veteran you know is in crisis — Veterans Crisis Line: dial 988, then press 1.

References

Sources

Human/clinical evidence retrieved from PubMed. Links resolve to the source publication.

Cherian KN, et al. Magnesium–ibogaine therapy in veterans with traumatic brain injuries. Nature Medicine, 2024. DOI
Alper K, et al. hERG Blockade by Iboga Alkaloids. Cardiovascular Toxicology, 2016. DOI
Litjens RPW, Brunt TM. How toxic is ibogaine? Clinical Toxicology, 2016. DOI
Brunt TM. Ibogaine and cardiovascular complications — prolonged QT interval and ventricular arrhythmias. Addiction, 2026. DOI
Glue P, et al. Influence of CYP2D6 activity on the pharmacokinetics and pharmacodynamics of ibogaine. J Clinical Pharmacology, 2015. DOI
Sullivan DR, et al. Cerebral perfusion is associated with blast exposure in military personnel without moderate or severe TBI. J Cerebral Blood Flow & Metabolism, 2020. DOI
Clark AL, et al. Dynamic association between perfusion and white matter integrity across time since injury in Veterans with TBI. NeuroImage: Clinical, 2016. DOI
Linnemann C, Lang UE. Pathways Connecting Late-Life Depression and Dementia (neuroinflammation, microglia, BDNF, vascular). Frontiers in Pharmacology, 2020. DOI
Zahoor SM, et al. Neurotoxic effects of metals on blood–brain barrier impairment and possible therapeutic approaches. Vitamins and Hormones, 2024. DOI
Pandics T, et al. Exposome and unhealthy aging: environmental drivers from air pollution to occupational exposures. GeroScience, 2023. DOI
Smith D, Strupp BJ. The scientific basis for chelation: animal studies and lead chelation. J Medical Toxicology, 2013. DOI
Dolenec P, et al. Psychoplastogen-based therapies: neuroplasticity via BDNF-TrkB-mTOR and immunomodulation. Pharmaceuticals, 2026. DOI